Prokaryotic ribosomes are 70S particles (smaller than eukaryotic 80S) composed of 30S and 50S subunits containing 16S/23S rRNA and ~50 ribosomal proteins. Translation begins coupled with transcription (no nuclear envelope), without 5' capping or 3' polyadenylation of mRNA. The structural and functional differences between prokaryotic and eukaryotic ribosomes make the prokaryotic ribosome a selective antibiotic target.
Compare 70S and 80S ribosomal structures and their assembly. Study the clinical resistance that arises from ribosomal mutations preventing antibiotic binding.
From your study of ribosome structure and peptidyl transferase activity, you know that ribosomes are RNA-protein machines that decode mRNA and catalyze peptide bond formation. Prokaryotic ribosomes perform exactly the same fundamental chemistry as eukaryotic ones, but they differ enough in structure, assembly, and regulation to create crucial opportunities for selective antibiotic targeting. Understanding these differences is the bridge between basic molecular biology and clinical medicine.
The prokaryotic ribosome sediments at 70S and dissociates into a 30S small subunit (containing 16S rRNA and ~21 proteins) and a 50S large subunit (containing 23S rRNA, 5S rRNA, and ~31 proteins). Compare this to the eukaryotic 80S ribosome with its 40S and 60S subunits — the size difference reflects additional rRNA expansion segments and more numerous ribosomal proteins in eukaryotes, but the catalytic core is conserved. The 16S rRNA in the 30S subunit plays a direct role in mRNA binding through base-pairing with the Shine-Dalgarno sequence — a purine-rich stretch upstream of the start codon that positions the mRNA correctly for translation initiation. Eukaryotic ribosomes use a completely different initiation mechanism involving 5′ cap recognition and scanning, so the Shine-Dalgarno interaction is a uniquely prokaryotic feature.
A defining feature of prokaryotic translation is coupled transcription-translation. Because bacteria lack a nuclear envelope, ribosomes begin translating an mRNA while RNA polymerase is still transcribing it. The leading ribosome sits just behind the polymerase, and this physical coupling has functional consequences: it prevents premature Rho-dependent transcription termination, allows rapid gene expression responses, and means that prokaryotic mRNA is never extensively processed — no 5′ capping, no 3′ polyadenylation (in the eukaryotic sense), and no splicing. Prokaryotic mRNAs are also frequently polycistronic, encoding multiple proteins in a single transcript organized in operons, with each open reading frame having its own Shine-Dalgarno sequence and start codon.
The structural differences between 70S and 80S ribosomes are what make the prokaryotic ribosome one of the most important drug targets in medicine. Antibiotics exploit specific features of the 30S or 50S subunit that are absent or different in eukaryotic ribosomes. For example, the decoding center of the 30S subunit — where aminoglycosides bind to cause mRNA misreading — has a different rRNA conformation than the corresponding eukaryotic site. The peptide exit tunnel of the 50S subunit, where macrolides bind to block elongation, likewise has prokaryote-specific features. Mutations in ribosomal RNA or proteins at these binding sites are a major mechanism of antibiotic resistance, which is why understanding the precise structural anatomy of the 70S ribosome is essential for both designing new antibiotics and predicting how resistance will evolve.